Financing ·
Indaptus Therapeutics authorizes up to $100M in common stock sales through H.C. Wainwright at-the-market program
INDPIndaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc. entered into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright & Co., LLC on August 28, 2026. This agreement supersedes the prior June 1, 2022 arrangement and authorizes the company to sell up to $100,000,000 in shares of common stock through an at-the-market program. The company will pay Wainwright a placement fee equal to 3.0% of the gross sales price for shares sold as agent. This filing updates disclosure regarding dilution in connection with a prospectus supplement filed on August 31, 2026. Indaptus Therapeutics operates in the biotechnology industry, focusing on the development of therapies.